Develops laser-based computing systems for cryptocurrency infrastructure, artificial intelligence workloads, and high-performance computing, alongside therapeutic drug candidates for autoimmune diseases and other conditions.
10-K for FY2025, filed Apr 15, 2026Q/C Technologies, Inc. (the “Company”) has historically been engaged in the development and commercialization of therapeutic platforms…View ↗
The Company’s core strategy is centered on leveraging an exclusive global licensing agreement with LightSolver Ltd. (“LightSolver”) to…View ↗
The qc-LPU100 is intended to address complex combinatorial and physical problems, including partial differential equations, and is targeted…View ↗
The Company’s laser-based computing business represents the Company’s primary strategic focus and is centered on the development…View ↗
Pharmaceutical BusinessView ↗
Isomyosamine is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including (but not…View ↗
$1.7M
10-K, filed Mar 25, 2020
$1.7M ↗
The company is developing computing systems for cryptocurrency infrastructure, artificial intelligence and high-performance computing users. It also develops therapeutic candidates for conditions including autoimmune diseases, epilepsy, pain and anxiety or depression.
10-K for FY2025, filed Apr 15, 2026The qc-LPU100 is intended to address complex combinatorial and physical problems, including partial differential equations, and is targeted…View ↗
The Company’s laser-based computing business represents the Company’s primary strategic focus and is centered on the development…View ↗
Isomyosamine is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including (but not…View ↗
Supera-CBD is a synthetic analog of CBD being developed to treat various conditions, including, but not limited to, epilepsy, pain and…View ↗
No. It lost $10.8M in FY2018.
10-K, filed Mar 25, 2020
10-K, filed Mar 25, 2020
−$10.1MView ↗
10-K, filed Mar 25, 2020
−$10.8MView ↗
10-K, filed Mar 25, 2020
−$8.6MView ↗
10-Q for Q2 FY2026, filed Aug 12, 2026
−$6.6MView ↗
8-K, filed Jul 2, 2026
On June 26, 2026, Q/C Technologies, Inc. (the “Company”) provided notice of its intention to terminate that certain Technology License and…View ↗
Shrinking. Revenue fell 62% in 4 years, from $4.4M in FY2014 to $1.7M in FY2018, about 22% a year.
Loading...